Table 5 Total treatment costs for with and without SEB scenarios in year 2
Patient type (CKD stage) | Treatments for anemia | Year 2 total costs ($) | |
|---|---|---|---|
Without SEB | With SEB | ||
Stage III/IV | Short acting ESA (SC) | 31,736,891 | 25,402,208 |
Long acting ESA (SC) | 33,013,420 | 26,423,942 | |
Epoetin SEB | - | 4,040,419 | |
Stage V | Short acting ESA (SC) | 26,456,982 | 21,176,169 |
Long acting ESA (SC) | 18,321,156 | 14,664,254 | |
Short acting ESA (IV) | 108,692,464 | 86,997,449 | |
Long acting ESA (IV) | 75,583,082 | 60,496,699 | |
Epoetin SEB | - | 14,292,950 | |
Total | 293,803,997 | 253,494,088 | |